Dimensioning technology developer MyFiziq Limited (ASX: MYQ) has signed a Memorandum of Understanding (MoU) with Canadian-based NuraLogix Corporation with the aim of developing state-of-the-art digital health screening solutions.
NuraLogix has developed patented technology which utilises a video camera like that found on a smartphone to take a 30 second selfie video of your face and determine a wide range of physiological and health related parameters such as: heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and much more.
The underlying technology is called Transdermal Optical Imaging (TOITM) and uses the video camera to extract blood flow information from your face. This information is then processed by advanced machine learning algorithms residing on NuraLogix’s cloud based Affective AI (Artificial Intelligence) Engine called DeepAffexTM.
The MyFiziq image dimensioning capabilities will be combined with DeepAffex and Transdermal Optical Imaging, to form a never before seen total health screen from a mobile phone.
MyFiziq CEO, Vlado Bosanac, said the combined digital capabilities of the two companies due to their patent coverage along with the unique offering is a one of a kind solution, that can be used whether you are 18 or 85 years of age.
Mr Bosanac said organisations around the world have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.
“We are looking to be less invasive from a personal perspective, allowing individuals the choice to screen themselves at home or work when they feel they may have been exposed and are showing any of the known symptoms,” he said.
This is an extremely exciting partnership for the companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled. Our offerings in a standalone environment have a deep patent suite,” Mr Bosanac said.
“When combining the company solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience.
“The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone. We have left the commercial terms aside at this point in time, as the initial targets are existing clients of MyFiziq and we will determine the commercial aspects of consumer use in conjunction with them, upon the successful evaluation by the partners.
“As mentioned, we will initially be offering the solution to only two of our partners, being The Serfaty Clinic in Brazil, and WeSure in Mainland China. These organisations have a combined population in their countries of 1,600,000,000 billion.
“With Brazil rapidly becoming the world’s 2nd most effected country by the current pandemic, we initiated this partnership specifically for Dr Serfaty in line with our earlier ASX release outlining the preliminary agreement targeting COVID-19 and the inherent risk Brazil was facing.
“As we explored and understood the ease of use when combining these world class technologies, we then felt it was a potential suitor for the solution we have been working hard on for WeSure / WeFit in the WeChat platform.”
